Europe Conjunctivitis Treatment Market Size, Share & Trends Analysis Report By Disease Type, By Drug Class (Anti-allergic, Antiviral, Artificial Tears, and Antibiotics), By Distribution Channel, By Country and Growth Forecast, 2023 - 2030
The Europe Conjunctivitis Treatment Market would witness market growth of 4.4% CAGR during the forecast period (2023-2030).
The conjunctivitis treatment landscape is shaped by scientific and medical breakthroughs and influenced by regulatory frameworks, healthcare policies, and the continuous evolution of diagnostic technologies. Ongoing research endeavours focus on improving the efficacy of existing treatments and developing novel therapeutic approaches, including immunomodulators and gene therapies, heralding a new era in ocular healthcare.
Furthermore, the primary application lies in developing and producing pharmaceuticals tailored to treat different forms of conjunctivitis. This includes formulating and manufacturing antibiotics for bacterial conjunctivitis, antiviral medications for viral forms, anti-allergic drugs for allergic conjunctivitis, and anti-inflammatory agents for managing inflammation. The market involves the development of medical devices and eye care products. This encompasses the creation of eye drops, ointments, and other topical treatments designed to alleviate symptoms and aid in the healing process.
According to the data from the Syndromic Surveillance Summary reported by the UK government, there was an increase observed in conjunctivitis consultations, particularly in children aged 5 to 14 years, between January 2023 and February 2023. Towards the end of February, the consultations were reported to be above seasonally expected levels. Moreover, in England, the incidence of conjunctivitis is 13 to 14 in 1000 people per year. The rates are higher in children under one to 5 years of age. This data underscores the importance of monitoring and addressing conjunctivitis trends, especially in vulnerable age groups, to ensure effective public health responses. Hence, the prevalence of conjunctivitis in the region is propelling the market's growth.
The Germany market dominated the Europe Conjunctivitis Treatment Market, by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $402.5 Million by 2030. The UK market is exhibiting a CAGR of 4.1% during (2023 - 2030). Additionally, The France market would experience a CAGR of 4.8% during (2023 - 2030).
Based on Disease Type, the market is segmented into Allergic Conjunctivitis, Viral Conjunctivitis, and Bacterial Conjunctivitis. Based on Drug Class, the market is segmented into Anti-allergic, Antiviral, Artificial Tears, and Antibiotics. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
List of Key Companies Profiled
- Novartis AG
- Gilead Sciences, Inc.
- GlaxoSmithKline PLC
- F. Hoffmann-La Roche Ltd.
- Merck & Co., Inc.
- Boehringer Ingelheim International GmbH
- AbbVie, Inc.
- AFT Pharmaceuticals
- Bausch Health Companies, Inc.
- Teva Pharmaceutical Industries Ltd.
By Disease Type
- Allergic Conjunctivitis
- Viral Conjunctivitis
- Bacterial Conjunctivitis
- Anti-allergic
- Antiviral
- Artificial Tears
- Antibiotics
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
- Chapter 1. Market Scope & Methodology
- 1.1 Market Definition
- 1.2 Objectives
- 1.3 Market Scope
- 1.4 Segmentation
- 1.4.1 Europe Conjunctivitis Treatment Market, by Disease Type
- 1.4.2 Europe Conjunctivitis Treatment Market, by Drug Class
- 1.4.3 Europe Conjunctivitis Treatment Market, by Distribution Channel
- 1.4.4 Europe Conjunctivitis Treatment Market, by Country
- 1.5 Methodology for the research
- Chapter 2. Market at a Glance
- 2.1 Key Highlights
- Chapter 3. Market Overview
- 3.1 Introduction
- 3.1.1 Overview
- 3.1.1.1 Market Composition and Scenario
- 3.2 Key Factors Impacting the Market
- 3.2.1 Market Drivers
- 3.2.2 Market Restraints
- 3.2.3 Market Opportunities
- 3.2.4 Market Challenges
- 3.3 Porter Five Forces Analysis
- Chapter 4. Europe Conjunctivitis Treatment Market, by Disease Type
- 4.1 Europe Allergic Conjunctivitis Market, by Country
- 4.2 Europe Viral Conjunctivitis Market, by Country
- 4.3 Europe Bacterial Conjunctivitis Market, by Country
- Chapter 5. Europe Conjunctivitis Treatment Market, by Drug Class
- 5.1 Europe Anti-allergic Market, by Country
- 5.2 Europe Antiviral Market, by Country
- 5.3 Europe Artificial Tears Market, by Country
- 5.4 Europe Antibiotics Market, by Country
- Chapter 6. Europe Conjunctivitis Treatment Market, by Distribution Channel
- 6.1 Europe Hospital Pharmacy Market, by Country
- 6.2 Europe Retail Pharmacy Market, by Country
- 6.3 Europe Online Pharmacy Market, by Country
- Chapter 7. Europe Conjunctivitis Treatment Market, by Country
- 7.1 Germany Conjunctivitis Treatment Market
- 7.1.1 Germany Conjunctivitis Treatment Market, by Disease Type
- 7.1.2 Germany Conjunctivitis Treatment Market, by Drug Class
- 7.1.3 Germany Conjunctivitis Treatment Market, by Distribution Channel
- 7.2 UK Conjunctivitis Treatment Market
- 7.2.1 UK Conjunctivitis Treatment Market, by Disease Type
- 7.2.2 UK Conjunctivitis Treatment Market, by Drug Class
- 7.2.3 UK Conjunctivitis Treatment Market, by Distribution Channel
- 7.3 France Conjunctivitis Treatment Market
- 7.3.1 France Conjunctivitis Treatment Market, by Disease Type
- 7.3.2 France Conjunctivitis Treatment Market, by Drug Class
- 7.3.3 France Conjunctivitis Treatment Market, by Distribution Channel
- 7.4 Russia Conjunctivitis Treatment Market
- 7.4.1 Russia Conjunctivitis Treatment Market, by Disease Type
- 7.4.2 Russia Conjunctivitis Treatment Market, by Drug Class
- 7.4.3 Russia Conjunctivitis Treatment Market, by Distribution Channel
- 7.5 Spain Conjunctivitis Treatment Market
- 7.5.1 Spain Conjunctivitis Treatment Market, by Disease Type
- 7.5.2 Spain Conjunctivitis Treatment Market, by Drug Class
- 7.5.3 Spain Conjunctivitis Treatment Market, by Distribution Channel
- 7.6 Italy Conjunctivitis Treatment Market
- 7.6.1 Italy Conjunctivitis Treatment Market, by Disease Type
- 7.6.2 Italy Conjunctivitis Treatment Market, by Drug Class
- 7.6.3 Italy Conjunctivitis Treatment Market, by Distribution Channel
- 7.7 Rest of Europe Conjunctivitis Treatment Market
- 7.7.1 Rest of Europe Conjunctivitis Treatment Market, by Disease Type
- 7.7.2 Rest of Europe Conjunctivitis Treatment Market, by Drug Class
- 7.7.3 Rest of Europe Conjunctivitis Treatment Market, by Distribution Channel
- Chapter 8. Company Profiles
- 8.1 Novartis AG
- 8.1.1 Company Overview
- 8.1.2 Financial Analysis
- 8.1.3 Segmental and Regional Analysis
- 8.1.4 Research & Development Expense
- 8.1.5 SWOT Analysis
- 8.2 Gilead Sciences, Inc.
- 8.2.1 Company overview
- 8.2.2 Financial Analysis
- 8.2.3 Research & Development Expenses
- 8.2.4 SWOT Analysis
- 8.3 GlaxoSmithKline PLC
- 8.3.1 Company Overview
- 8.3.2 Financial Analysis
- 8.3.3 Regional Analysis
- 8.3.4 Research & Development Expense
- 8.3.5 Recent strategies and developments:
- 8.3.5.1 Trial and Approval
- 8.3.6 SWOT Analysis
- 8.4 F. Hoffmann-La Roche Ltd.
- 8.4.1 Company Overview
- 8.4.2 Financial Analysis
- 8.4.3 Segmental and Regional Analysis
- 8.4.4 Research & Development Expense
- 8.4.5 SWOT Analysis
- 8.5 Merck & Co., Inc.
- 8.5.1 Company Overview
- 8.5.2 Financial Analysis
- 8.5.3 Segmental and Regional Analysis
- 8.5.4 Research & Development Expenses
- 8.5.5 Recent strategies and developments:
- 8.5.5.1 Partnerships, Collaborations, and Agreements:
- 8.5.6 SWOT Analysis
- 8.6 Boehringer Ingelheim International GmbH
- 8.6.1 Company Overview
- 8.6.2 Financial Analysis
- 8.6.3 Regional & Segmental Analysis
- 8.6.4 Research & Development Expenses
- 8.6.5 SWOT Analysis
- 8.7 AbbVie, Inc.
- 8.7.1 Company Overview
- 8.7.2 Financial Analysis
- 8.7.3 Regional Analysis
- 8.7.4 Research & Development Expense
- 8.7.5 SWOT Analysis
- 8.8 AFT Pharmaceuticals
- 8.8.1 Company Overview
- 8.8.2 Financial Analysis
- 8.8.3 Segmental Analysis
- 8.8.4 Research & Development Expenses
- 8.8.5 SWOT Analysis
- 8.9 Bausch Health Companies, Inc
- 8.9.1 Company Overview
- 8.9.2 Financial Analysis
- 8.9.3 Segmental and Regional Analysis
- 8.9.4 Research & Development Expense
- 8.9.5 Recent strategies and developments:
- 8.9.5.1 Acquisition and Mergers:
- 8.9.6 SWOT Analysis
- 8.10. Teva Pharmaceutical Industries Ltd.
- 8.10.1 Company Overview
- 8.10.2 Financial Analysis
- 8.10.3 Regional Analysis
- 8.10.4 Research & Development Expenses
- 8.10.5 Recent strategies and developments:
- 8.10.5.1 Product Launches and Product Expansions:
- 8.10.6 SWOT Analysis
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook